Maternal drug abuse and human term placental xenobiotic and steroid metabolizing enzymes in vitro. by Paakki, P et al.
Articles
Maternal Drug Abuse and Human Term Placental Xenobiotic and Steroid
Metabolizing Enzymes in Vitro
Pauliina Paakki,' Helene Stockmann Marjatta Kantola,3 Peruka Wagner,4 Urs Lauper,4 Renate Huch,4 Eivor
Elovaara,2 Pertti Kirkinen,5 andMarkku Pasanen"6
1Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland; 2Finnish Institute of Occupational Health, Helsinki,
Finland; 3Department of Chemistry, University of Kuopio, Kuopio, Finland; 4Department of Obstetrics, University of Zurich, Zurich,
Switzerland; 5Department of Gynecology and Obstetrics, University of Kuopio, Kuopio, Finland; 6National Agency for Medicines,
Helsinki, Finland
We evaluated the impact ofmaternal drug abuse at term on human placental cyto me P450
(CYP)-mediated (Phase I) xenobiotic and steroid-metabolizing activities [aromatase, 7-ethoxyre-
sorufin O-deethylase (EROD), 7-etoxycoumarin Oadeethylase (ECOD), pyrene 1-hydroxylase
(PIOH), and testosterone hydroxylasel, and androstenedione-forming isomerase, NADPH
quinone oxidoreductase (Phae II), UDP-glucuronosyltransferase (UGT), andglutathione &trans-
ferase (GST) activities in vitro. Overall, the formation ofandrostenedione, P1OH, and testos-
terone hydroxylase was statistically significant between control and drug-abusing subjects; we
observed no significant differences in any other ofthe phase I and II activities. In placentas from
drug-abusing mothers, we found sigificant correlations between ECOD and P1OH activities
(p < 0.001), butnot betweenECOD andaromatase orP1OH and EROD actiities; wealso found
significant correlations between bloodcotinine and UGTactivities (p< 0.01). Incontrast, in con-
trols (mothers who did not abuse drugs but did smoke c s), the P1OH activity correlated
with ECOD, EROD (p < 0.001), and testosterone hydroylae (p < 0.001) activities. Our results
(wider variation in ECOD activity among tissue from drug-abusing mothers and the sigificant
correlation between P10H and ECOD acttiviies, but not with aromatase or EROD activities)
indicate that maternal drug abuse results in an additive effect in enhancing placental xenobiotic
metabolizing enzymes when the mother also smokes cigaettes; this may be due to enhancing a
"silent" CYP form, or a new placental CYP fonn may be activated. The change in the steroid
metabolism profile in vib suggests that maternal drug abuse may alter normal hormonal home-
ostasis during pregnancy. Jey words: barbiturates, benzodiazepines, cocaine, cytochrome P450,
drug metabolism, gestation, methadone, opiates, pregnancy, smoking, steroids. Environ Healh
Perspect108:141-145 (2000). [Online 7January2000]
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Illicit use of psychostimulants during preg-
nancy is an increasing problem in modern
society, resulting in increased numbers of
adverse pregnancy outcomes such as miscar-
riages, vaginal bleeding, and cognitive effects
in newborns. However, the effect of mater-
nal drug abuse on the metabolic characteris-
tics ofthe human fetoplacental unit has not
been evaluated thoroughly; therefore, the
risk for underestimations or overestimations
ofmetabolism-based outcomes is obvious.
Human placenta produces and metabo-
lizes estrogenic steroids and metabolizes xeno-
biotics. Cytochrome P450 (CYP) enzymes
participate in thesynthesis and catabolism of
steroid hormones; they also metabolize vita-
mins, fattyacids, and awide range ofmedic-
inal drugs and chemical carcinogens (1,2).
Human placental microsomal CYP enzymes
catalyze the synthesis of estrogens (3) and
metabolize and, in some cases, activate xeno-
biotic compounds (4).
Human placenta at term expresses only a
few functional xenobiotic-metabolizing CYP
enzymes (4-6). Thus far, only cigarette
smoke-inducible CYPlAI (5) and ethanol-
inducible CYP2E1 (7) havebeen characterized
at the protein and mRNA levels in human
placenta, although at fill term CYPlAI, 2E1,
2F1, 3A4, 3A5, and 3A7 mRNAs can be
detected (6). Several drug therapies induding
phenobarbital and phenobarbital-like induc-
ers such as carbamazepine have failed to affect
placental CYP-associated activities (8-10).
In the present study, we examined the
effect ofmaternal drugabuse on human pla-
cental xenobiotic- and steroid-metabolizing
phase I and II activities at term in vitro.
This is the first study to demonstrate that
UDP-glucuronosyltransferase (UGT) activi-
ty is individually expressed and detectable in
all placental samples and that maternal drug
abuse may alter or at least enhance the
metabolic capacity of the human placenta,
which may also affect the phenotype of
the newborn.
Materials and Methods
Subjects. Thisstudywas carried outaccording
to the principles of the Declaration of
Helsinki. The study protocol and the use of
human tissue was approved by the ethics
committees of the University of Zurich
(Zurich, Switzerland) and the University of
Oulu (Oulu, Finland). All women who par-
ticipated in the study gave their informed
consent. Human placental samples were col-
lectedat term fromdrug-abusing (n = 13) and
non-abusing (n = 24) mothers; cigarette
smokingwas allowedandverifiedbymaternal
venous and umbilical cord blood determina-
tions. In the clinical history ofdrug-abusing
mothers, there was extensive use ofcannabis,
methadone, opiates, cocaine, benzodiazepine,
and barbiturates (Table 1). In the urine
analyses at term, the following drugs were
detected: cannabis, methadone, opiates,
codeine, morphine, heroin, benzodiazepine,
and barbiturates. Infectious etiology was
excluded by hepatitis antibody determina-
tions. Nine out of 14 deliveries were sponta-
neous vaginal delivery, ofwhich one case was
vacuum assisted, and the rest were Cesarean
deliveries. The control group consisted of24
healthy subjects with normal pregnancies.
Among these non-drug abusing mothers, we
found no evidenceofdrug use in urine analy-
ses, and self-reported cigarette smoking var-
ied from 0 to 20 cigarettes/day. Fifteen ofthe
cases had normal vaginal delivery (two
required forceps and one was vacuum assist-
ed), and nine had Cesarean deliveries because
of fetopelvic disproportion. Demographic
and perinatal data ofthe subjects are present-
ed inTable 1.
None of the fetuses presented antenatal
or peripartal signs of intrauterine distress
(pathologic cardiotocographic or Doppler
findings). Postpartal recovery of all mothers
and newborns was normal. We found no sta-
tistically significant differences between the
two groups in weights offetuses or placentas
(data notshown) or in gestation times.
Preparation ofplacental samples.
Immediately after delivery, a physical exami-
nation was performed and connective tissues
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and coagulated blood were removed.
Placental tissue was rinsed in cold NaCl
(0.9%) solution and gently dried between
paper towels; small pieces of tissue (10 g)
were taken from the central part ofeach pla-
centa and immersed in liquid nitrogen.
Placental samples were stored at -70°C until
microsomes were prepared (within 2
months). To minimize decontamination of
microsomes by mitchondrial fraction (11),
microsomes were isolated andwashed in 150
mM KCl, 10 mM EDTA buffer (pH 7.4)
(12) and suspended in 100 mM potassium
phosphate, 1 mM EDTA, 20% glycerol
buffer (pH 7.4), to give the final protein
content of 15-20 mg/mL (13).
Biochemical assays. We determined
microsomal protein concentrations by the
bicinchonic acid method (14). The follow-
ing cytochrome P450-dependent metabolic
reactions were determined using standard
assays: 7-ethoxycoumarin O-deethylase
activity (ECOD) was measured by the
method ofGreenlee and Poland (15) using 2
mM 7-ethoxycoumarin as a substrate; 7-
ethoxyresorufin O-deethylase (EROD; 0.1
mM substrate) activity was determined
according to Burke et al. (16). We used the
method ofWaxman et al. (17) to determine
testosterone hydroxylase activity using a
substrate concentration of 50 mM. Four
unidentified metabolites and androstene-
dione were formed in each sample, the
intensities ofwhich were comparable in each
placenta based on the autoradiography films.
For the activity determinations, we selected
the chromatographically slowest metabolite
band with a relative flow (Rf) value of
approximately 0.433. The Rf value for
testosterone was 0.867. None ofthe metabo-
lites comigrated with 613-hydroxytestos-
terone. Aromatase activity was determined
according to the method of Pasanen (18)
using a substrate concentration of 10 nM.
The pyrene 1-hydroxylase (PIOH) assay
mixture (270 ,uL final volume) contained 50
mM K-Na phosphate buffer-0.15 M KCG
(pH 7.4), 50 pg microsomal protein, 100 pg
bovine serum albumin, 1 mM NADPH, and
93 pM pyrene (dissolved in 5 pL DMSO).
After incubation at 37°C for 10 min, the
reaction was stopped with 0.15% ZnSO4 .
H20 and cooled on ice. After 600 jiL ace-
tonitrile was added to the mixture, it was
mixed for 10 sec and centrifuged for 10 min
at 10,000 x gat 20C. We analyzed a 50-pL
sample for 1-hydroxypyrene using a
Spherisorb S3 OD (4.6 x 100 mm) column
(Phase Separation Ltd, Deeside Industrial
Park, UK), isocratic runs with acetoni-
trile-0.5% acetic acid in water (75:25), and a
Shimadzu HPLC/CLASS VP 5.021 software
chromatography data system (Shimadzu,
Kyoto, Japan) equipped with an autoinjector
and an RF-1OA fluorometric detector (Xex
242 nm, Xem 388 nm). We used 1-hydroxy-
pyrene calibration curves (0, 30, 60, 100,
and 200 nM) for peak area quantification.
The enzyme reaction was linear up to
30 min.
NADPH:quinone oxidoreductase (NQO)
is a flavoprotein that catalyzes two-electron
reduction of quinones and their derivatives,
exerting a protective effect against chemical
mutagenicity and toxicity. NQO was recorded
at 600 nm as the dicoumarol (10 mM)-sensi-
tive reduction of2,6-dichlorophenolindophe-
nol with NADPH as the electron donor. The
assay mixture (1.2 mL), which contained
0.3-1 mg cytosolic protein from placental
samples, was preincubated at 30'C for 5 min
before addition ofNADPH and the measure-
ment in aShimadzu 3,000 double beam spec-
trophotometer (Shimadzu) (19).
Glutathione S-transferase (GST) activity
toward 1-chloro-2,4-dinitrobenzene was
recorded spectrophotometrically at room
temperature according to Habig et al. (20)
using 0.04.-0.12 mg cytosolic protein from
placental samples in a 2.5-mL assay mixture.
We determined UGT activity toward 1-
hydroxypyrene (93 pM) as the rate ofmicro-
somal glucuronidation at 37C in a 10-min
assay according to the fluorometric HPLC
method of Luukkanen et al. (21). We used
the Shimadzu HPLC apparatus described
above for product identification and calibra-
tion of1-hydroxypyrene-P-D-glucuronide.
Serum cotinine levels from maternal
venous blood and umbilical cord blood sam-
ples were determined by the method of
Kolonen and Puhakainen (22) with minor
modifications. For the analyses we used a
programmable HPLC (Waters 600 E;
Waters, Caguas, Puerto Rico) with UV
detection (Schoeffel Instrument Group,
Labtronic Ltd, Vantaa, Finland) and with a
Rheodyne 7125 injector (Rheodyne, L.P.,
Rohnert Park, CA). Separation was carried
out with a silica column (Spherisorb S5
ODS2, 25 cm x 4.6 mm; Phase Separation
Ltd) using 40% methanol-60% 0.1 M
phosphate buffer, pH 4.5, and a flow rate of
0.5 mL/min. Benzimidazole was used as an
internal standard.
All enzyme assays were performed in a
blinded fashion as duplicates.
Chemicals. 7-Ethoxycoumarin, 2,6-
dichlorophenolindophenol, 1-chloro-2,4-
dinitrobenzene, Tween-80, bicinchonic acid,
bovine serum albumin, nicotinamide ade-
nine dinucleotide phosphate (reduced),
pyrene, 1-hydroxypyrene, and testosterone
were from Sigma (St. Louis, MO). Resorufin
was obtained from Aldrich (Milwaukee,
WI). 7-Ethoxyresorufin was purchased from
Pierce (Rockford, IL) and 4-[I4C]-testos-
terone and Hyperfilm MP autoradiography
films were obtained from Amersham
(Amersham, UK). 1,2-[3H]-androst-4-ene-
3,17-dione was obtained from New England
Nuclear (Southampton, Hants, UK).
Nonradioactive 4-androsten-3,17-dione and
testosterone were from Sigma. Silica gel G60
F254 thin layer chromatography plates were
obtained from E. Merck (Darmstadt,
Germany). All other chemicals were of at
least analytical grade. 1-Hydroxypyrene-P-D-
glucuronide was synthesized and purified by
L. Luukkanen, Helsinki University.
Statistical analysis. Statistical signifi-
cance was determined by Mann-Whitney
U-test. p-Values < 0.05 were considered
statistically significant.
Results
Table 1 presents demographic data from
mothers whose placentas were used in this
study.
The comparison of xenobiotic-metabo-
lizing activities and maternal venous and
umbilical cord plasma cotinine concentra-
tions from the drug-abusing group (the
study group) and the cigarette-smoking con-
trols are summarized in Table 2. Briefly, of
the phase I enzyme activities assayed in this
Table 1. Demographic and perinatal data ofthe study and control groups.
Parameter Studygroup (n = 13) Control group (n =24)
Maternal age (years) 28.4 ± 6.1 (n= 13) 29.7 ± 4.0 (n= 24)
Number of previous pregnancies 1.5 ± 0.67 In= 12) 2.3 ± 0.9 (n=23)*
Duration of pregnancy(weeks) 38.3 ± 1.9(n= 13) 38.8 ± 1.7 (n= 24)
Consumption of alcohol (self reported) 3 L beer/day(n= 1) None
Drugs ofabuse
Cannabis 115a ND/ND
Methadone 7/8 ND/ND
Heroin (3/2) ND/ND
Hashish 1/ND ND/ND
Benzodiazepines 3/4 ND/ND
Neuroleptics 5/NA ND/ND
Morphine 3/6 ND/ND
Codeine ND/3 ND/ND
Cocaine 2/ND ND/ND
NS, not detectable; NA, not analyzed. Values shown are mean ± SD.
aSelfreported/urine analysis. *p<0.05.
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study, pyrene hydroxylation (p < 0.000),
testosterone hydroxylation (p < 0.011), and
formation of androstenedione (p < 0.037)
exhibited statistically significant differences
between the study and control groups.
Phase II activities were not enhanced con-
comitantly with the phase I activities in the
study group. Both groups consisted ofactive
cigarette smokers, as indicated by blood
cotinine analysis. However, we did not find
significantly higher cotinine concentrations
in the blood of drug-abusing mothers than
in controls.
Table 3 is a summary of the correlation
matrix ofall the determinations in the study
group. Significant correlations existed only
between PIOH and ECOD activities
(p < 0.01), and between blood cotinine and
microsomal UGT levels (p < 0.01). We
found no significant correlation between
P1GH and aromatase, P1OH and EROD,
or P1OH and testosterone hydroxylation.
The correlation matrix containing deter-
minations in the cigarette smoking control
group is summarized in Table 4. In this
group, we found significant positive correla-
tions among ECOD, EROD, and PIOH
activities (p < 0.001). Testosterone hydroxy-
lase activity correlated with aromatase,
ECOD, and EROD activities (p < 0.05).
Discussion
This is the first study to demonstrate that
maternal drug abuse significantly affects
human placental xenobiotic- and steroid-
metabolizing activities; steroid-metabolizing
and pyrene 1-hydroxylation activities signifi-
cantly differed between the drug-abusing
study group and the cigarette-smoking con-
trols. Moreover, EROD activity, a well-
known CYPlAI marker activity in the
human placenta, did not correlate with
P1OH (r = 0.019) activity measurements in
drug abusers, whereas it did correlate in ciga-
rette-smoking controls (r= 0.984;p< 0.001)
suggesting the expression of a possibly new
catalytic characteristic (or a "silent" form in
normal conditions) in the placentas ofdrug
abusers. The observed trend, reduction of
GST and UGT activities among abusers,
may also refer to increased metabolism-relat-
ed chemical and oxidative stress in the fetal
tissues caused bymaternal illicit drug use.
Thus far, placental xenobiotic-metaboliz-
ingactivities have been characterized primar-
ily using cigarette smoking as a xenobiotic
load (23), whereas placentas from drug
abusers have received only minor interest.
However, contaminated food stuffs (24) and
polluted air (25) may enhance placental
xenobiotic-metabolizing activities, namely,
Table 2. Comparison ofthe biochemical data between the study and control groups.
Parameter
Androstenedione formation (pmol/mg x min)
Aromatase (pmol/mg x min)
ECOD (pmol/mg x min)
EROD (pmol/mg xmin)
P1OH (pmol/mg xmin)
Testosterone hydroxylase (pmol/mg x min)
Cotinine, umbilical cord (mg/mL)
Cotinine, maternal vena (mg/mL)
GST(nmol/mg xmin)
NQO (pmol/mg xmin)
UGT(pmol/mg xmin)
Study group
(n= 13)
12.3 ± 4.75 (n= 13)
27.4± 12.1 (n= 13)
89.7 ± 72.2 (n= 13)
119± 182(n= 13)
46.4 ±50.5(n= 13)
10.7 ± 8.43(n= 12)
4.38 ± 5.44(n= 13)
4.64 ± 5.87 (n= 13)
179±72(n=13)
2,359 ± 1,785 (n= 12)
3.97 ± 2.88 (n= 13)
Control group
(n=24)
9.22 ± 6.15(n= 22)
24.6 ± 10.5 (n=24)
76.0 ± 62.7 (n=23)
113±226(n=23)
11.8±22.0(n=23)
5.43 ± 3.31 (n= 23)
3.97 ± 4.67 (n=24)
3.37 ± 3.78 (n= 24)
206±53(n=23)
2,388 ± 1,305 (n= 22)
13.2 ± 23.5 (n= 23)
p-Value"
0.037
0.479
0.253
0.454
0.000
0.011
0.672
0.79
0.149
0.929
0.626
Values shown are mean ± SD.
'As determined by Mann-Whitney U-test.
CYPlAl expression. The present study
group consisted ofindividuals with multiple
drug loads and uncommon and varied
lifestyles. Nevertheless, the overall metaboliz-
ing characteristics in these individuals did
not differ significantly from controls when
the classical indicators of placental drug
induction were used. This study suggests
some new biochemical marker activities,
such as testosterone hydroxylase, P1OH,
and UCT, which until now have not been
intensively studied in placenta, and responds
to maternal chemical exposure.
In rodents, the hepatic GST activity
increases due to xenobiotics. However,
human placental GST does not seem
enhanced, at least not because of cigarette
smoking. We have shown that GST levels
reflect the activity of steroid-metabolizing/
synthesizing functions (23) rather than indi-
cate an increase in the xenobiotic load. The
present results agree with our earlier study
(23); placental GST levels decreased rather
than increased in response to the maternal
drug load. The phenomenon was identical
when humans were exposed to industrial
chemicals or radioactive ionization, both fac-
tors that enhance oxidative stress and
decreaseplacental GST levels (26).
UGT activity has been detected with a
wide interindividual variation in human liver
(27) and placenta (28). An early study
demonstrated that placental UGT activity
does not positively correlate to maternal cig-
arette-smoking status (28). According to our
study in placenta, placental UGT activity
responds to maternal cigarette smoking,
detected by blood cotinine determinations,
as decreased absolute enzymatic activity lev-
els and a marginal positive correlation.
However, in placentas from drug-abusing
mothers, a strong correlation was observed.
This is the first report to describe such a
causality, suggesting that in the placenta the
UGT activity does not readily respond to
maternal cigarette smoking and, like the
Table 3. Correlation matrixforthe study group.
Androstenedione Testosterone Cotinine Cotinine
formation Aromatase ECOD EROD P1OH hydroxylase (UC) (MV) GST NQO UGT
Androstenedione 1 -0.0150 0.107 -0.193 0.207 0.445 -0.377 -0.330 -0.044 0.063 0.289
formation
Aromatase 0.336 1 0.493 -0.006 0.217 0.622* -0.114 -0.015 0.164 -0.452 0.337
ECOD 0.107 0.493 1 0.332 0.773** -0.150 -0.147 -0.150 0.390 0.099 -0.030
EROD -0.193 -0.006 0.332 1 0.019 -0.330 0.252 0.197 -0.205 0.001 0.086
P1OH 0.207 0.217 0.773** 0.019 1 -0.281 -0.073 -0.126 0.302 0.266 0.035
Testosterone 0.445 0.622* -0.150 -0.330 -0.281 1 -0.142 -0.067 0.051 -0.401 0.302
hydroxylase
Cotinine (UC) -0.377 -0.114 -0.147 0.252 -0.073 -0.142 1 0.982# 0.383 0.141 0.733**
Cotinine (MV) -0.330 -0.015 -0.150 0.197 -0.126 -0.067 0.982# 1 0.405 0.039 0.767**
GST -0.044 0.164 0.390 -0.205 0.302 0.051 0.383 0.405 1 0.409 0.302
NQO 0.063 -0.452 0.099 0.001 0.266 -0.401 0.141 0.039 0.409 1 0.048
UGT 0.289 0.337 -0.030 0.086 0.035 0.302 0.733** 0.767** 0.302 0.048 1
Abbreviations: MV, maternal vena; UC, umbilical cord.
*p< 0.05; **p < 0.01;#p < 0.001.
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Table4. Correlation matrixforthe control group.
Androstenedione Testosterone Cotinine Cotinine
formation Aromatase ECOD EROD P1OH hydroxylase (UC) (MV) GST NGO UGT
Androstenedione 1 -0.354 -0.037 -0.197 -0.188 -0.178 0.021 0.008 -0.011 -0.199 0.022
formation
Aromatase -0.354 1 0.033 0.355 0.355 0.700# 0.159 -0.064 0.135 0.206 -0.148
ECOD -0.037 0.033 1 0.806# 0.821# 0.210 -0.162 -0.275 0.082 -0.099 -0.138
EROD -0.197 0.355 0.806# 1 0.984# 0.471* -0.104 -0.156 0.064 -0.095 -0.043
P1OH -0.188 0.355 0.821# 0.984# 1 0.479* -0.051 -0.098 0.129 -0.169 -0.013
Testosterone -0.178 0.700# 0.210 0.471* 0.497* 1 0.244 -0.053 0.097 -0.008 0.274
hydroxylase
Cotinine (UC) 0.021 0.159 -0.162 -0.104 -0.051 0.244 1 0.884# 0.013 0.148 0.055
Cotinine (MV) 0.008 -0.064 -0.156 -0.141 -0.098 -0.053 0.884# 1 -0.069 0.017 0.019
GST -0.011 0.135 0.082 0.064 0.129 0.097 0.013 -0.069 1 0.111 0.242
NQO -0.199 0.206 -0.099 -0.095 -0.169 -0.008 0.148 0.017 0.111 1 -0.176
UGT 0.022 -0.148 -0.138 -0.043 -0.013 0.274 0.055 0.019 0.242 -0.176 1
Abbreviations: MV, maternal vena; UC, umbilical cord.
*p< 0.05;#p<0.001.
GST activity, may reflect changes in oxdative
stress or hormonal homeostasis rather than
classical xenobiotic-metabolizing capacity.
We detected an effect caused by mater-
nal drugabuse thatwas additive as compared
to the effect detected after maternal cigarette
smoking. Moreover, we detected the exis-
tence of a new catalytic activity, PIOH,
which correlated consistently with the
ECOD activity, but correlated with the
EROD or testosterone hydroxylase activity
only in cigarette-smoking controls. Our ear-
lier study demonstrated that the ECOD
activity could serve as a general marker for
enhanced placental xenobiotic activities cor-
relating with EROD and aromatase activity
levels in placentas ofsmokers and nonsmok-
ers (23,29). In the present study group,
neither the ECOD nor the P1OH levels cor-
related with EROD determinations or with
any other catalytic determination induding
aromatase activity. However, we cannot
exclude the possibility that, in normal condi-
tions, a "silent" CYP form could be responsi-
ble for P1OH activity because at least 11
distinct human CYP forms can catalyze
ECOD activity (30). Interestingly, aro-
matase (CYP19) accepts cocaine, aflatoxin
Bi, or 7-ethoxycoumarin as substrates
(31-34). However, the CYPJ9 gene is not
affected by maternal cigarette smoking (23)
or drinking ofalcohol (35). There is no sig-
nificant correlation between P1OH and aro-
matase activities; this supports the view of
the expression ofa newcatalytic activity.
Our earlier studies have shown that
human placenta expresses more CYP genes
at the mRNA level in the first trimester than
at term (6,36). This may mean that at the
phase of early development and growth of
the fetoplacental unit, the expression of
those CYP genes which are not urgently
needed for thewell-being ofthe human fetus
could be switched off. However, maternal
drug abuse could serve as a relevant enhanc-
ing stimulus to maintain the expression of
specific CYP form(s) throughout the time
ofgestation.
Could these metabolic disturbances be
reflected in later development ofthe affected
fetus or child? An outstanding example of a
compound that affected gestational hormonal
homeostasis is diethylstilbestrol, with well-
known health effects appearing at adoles-
cence. However, in these cases, no evaluation
of placental xenobiotic or steroid-metaboliz-
ing capacity was carried out at delivery but
only afterward, and no association for adverse
events and placental metabolism could be
demonstrated (37).
During the 9 months ofpregnancy, the
human placenta passes through all its onto-
genic developmental phases with the associ-
ated changes in its metabolic characteristics.
During that period ofgrowth and specializa-
tion, the human placenta is apotential target
for unwanted metabolic responses caused by
maternal diseases or xenobiotics. For exam-
ple, maternal intrahepatic cholestasis of
pregnancy has been shown to decrease over-
all placental metabolic capacity at term (38),
and maternal clinical use of corticosteroids
dramatically suppresses placental aromatase
at term (39). However, the final clinical
responses may be recorded only after a long
delay, as with diethylstilbestrol. Responses
such as these among drug abusers may be
shown in future cohort studies.
Are there any implications to the current
drug therapy during pregnancy? Results in
the present study, generated using classical
analytical methods, show no dramatic differ-
ences in metabolic characteristics or macro-
scopic characteristics between the study and
control groups. However, in our extended
panel of analysis, some significant correla-
tions were observed. Maternal drug abuse
caused an additive effect in xenobiotic-
metabolizing characteristics as compared to
the cigarette-smoking control group. It is
possible that the combination ofdrug abuse
with any other medication could complicate
the expression of placental metabolizing
enzymes; these issues are still to be resolved.
Therefore, all term placentas from mothers
who use any relevant medication or abuse
drugs should be evaluated in terms of total
xenobiotic-metabolizing activity in vitro.
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